Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop a lead compound series to identify potential therapeutics to treat HLBS diseases and disorders. Following successful completion of the program, it is expected that the lead compound series will be poised to move forward for preclinical testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. For projects that are at an earlier stage (target identification and validation), a companion initiative is available (RFA-HL-20-023). Through Catalyze, the small molecule and biologics initiatives have companion initiatives that support development of devices, diagnostics and tools (RFA-HL-20-024 and RFA-HL-20-028). See website for additional information.


  • Letter of Intent: 30 days prior to the application due date
  • Application Due Dates: November 8, 2019, March 9, 2020, March 9, 2021, July 9, 2021
  • AIDS Application Due Dates: December 10, 2019, May 11, 2020, May 11, 2021, August 11, 2021

RFA-HL-20-027 Expiration Date: August 12, 2021

Agency Website

Amount Description

Application budgets must not exceed direct costs of $350,000 per year.

The total budget (Federal award and non-Federal matching contributions) should reflect the actual needs of the overall proposed project. Annual project budgets should reflect the actual costs anticipated in each year.

Matching Fund Requirement: The recipient is required to provide at least a 0.25:1 non-Federal match of the Federal direct costs requested.

The maximum project period is up to two years. The scope of the proposed project should determine the requested project award period.

Funding Type





Medical - Translational

External Deadline

March 9, 2020